Biomarkers in systemic lupus erythematosus: Challenges and prospects for the future

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 4, 2013, Pages 210-233

  Liu, Chau Ching ^a   Kao, Amy H ^b   Manzi, Susan ^b   Ahearn, Joseph M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

biomarker; lupus; SLE; systemic lupus erythematosus

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CD40 LIGAND; CD70 ANTIGEN; CD9 ANTIGEN; DNA METHYLTRANSFERASE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERFERON; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MICRORNA; MICRORNA 146A; MICRORNA 148A; MICRORNA 21; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOSOME ANTIBODY; PERFORIN; RANTES; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DIAGNOSTIC ERROR; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DNA METHYLATION; DNA MODIFICATION; DRUG RESEARCH; EPIGENETICS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; PATHOGENESIS; PATIENT CODING; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; RHEUMATOLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; TWIN CONCORDANCE; URINALYSIS; VALIDATION PROCESS;

EID: 84887295729     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13485503     Document Type: Article

References (198)

1. Adhya Z. Borozdenkova S. Karim M. (2011) The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant 26: 3273–3280.
2. Ahearn J. Liu C. Kao A. Manzi S. (2012) Biomarkers for systemic lupus erythematosus. Transl Res 159: 326–342.
3. Akhter E. Burlingame R. Seaman A. Magder L. Petri M. (2011) Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 20: 1267–1274.
4. Allan R. Zueva E. Cammas F. Schreiber H. Masson V. Belz G. et al. (2012) An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature 487: 249–253.
5. Apostolidis S. Lieberman L. Kis-Toth K. Crispin J. Tsokos G. (2011) The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 31: 769–779.
6. Aringer M. Stummvoll G. Steiner G. Koller M. Steiner C. Hofler E. et al. (2001) Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 40: 876–881.
7. Awasthi A. Carrier Y. Peron J. Bettelli E. Kamanaka M. Flavell R. et al. (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8: 1380–1389.
8. Baechler E. Batliwalla F. Karypis G. Gaffney P. Ortmann W. Espe K. et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100: 2610–2615.
9. Baltimore D. Boldin M. O'Connell R. Rao D. Taganov K. (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9: 839–845.
10. Bartel D. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
11. Basu D. Liu Y. Wu A. Yarlagadda S. Gorelik G. Kaplan M. et al. (2009) Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells. J Immunol 183: 3481–3487.
12. Batal I. Liang K. Bastacky S. Kiss L. McHale T. Wilson N. et al. (2012) Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus 21: 13–26.
13. Bauer J. Baechler E. Petri M. Batliwalla F. Crawford D. Ortmann W. et al. (2006) Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3 (12): e491.
14. Bauer J. Petri M. Batliwalla F. Koeuth T. Wilson J. Slattery C. et al. (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60: 3098–3107.
15. Becker-Merok A. Nikolaisen C. Nossent H. (2006) B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15: 570–576.
16. Bennett L. Palucka K. Arce E. Cantrell V. Borvak J. Banchereau J. et al. (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711–723.
17. Biesen R. Demir C. Barkhudarova F. Grun J. Steinbrich-Zollner M. Backhaus M. et al. (2008) Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 58: 1136–1145.
18. Bigler C. Lopez-Trascasa M. Potlukova E. Moll S. Danner D. Schaller M. et al. (2008) Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis 51: 624–629.
19. Bird A. (2007) Perceptions of epigenetics. Nature 447: 396–398.
20. Bolignano D. Donato V. Coppolino G. Campo S. Buemi A. Lacquaniti A. et al. (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52: 595–605.
21. Brunner H. Bennett M. Mina R. Suzuki M. Petri M. Kiani A. et al. (2012) Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum 64: 2687–2697.
22. Brunner H. Mueller M. Rutherford C. Passo M. Witte D. Grom A. et al. (2006) Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 54: 2577–2584.
23. Bruns A. Blass S. Hausdorf G. Burmester G. Hiepe F. (2000) Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 43: 2307–2315.
24. Cameron J. (1999) Lupus nephritis. J Am Soc Nephrol 10: 413–424.
25. Carthew R.W. Son theimer E.J. (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642–655.
26. Cervera R. Vinas O. Ramos-Casals M. Font J. Garcia-Carrasco M. Siso A. et al. (2003) Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62: 431–434.
27. Chabre H. Amoura Z. Piette J. Godeau P. Bach J. Koutouzov S. (1995) Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 38: 1485–1491.
28. Chan R. Lai F. Li E. Tam L. Chow K. Li P. et al. (2006) The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant 21: 1534–1540.
29. Cheema G. Roschke V. Hilbert D. Stohl W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44: 1313–1319.
30. Chen Z. Wang G. Wang G. Li X. (2012) Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. Clin Rheumatol 31: 1323–1329.
31. Chun H. Chung J. Kim H. Yun J. Jeon J. Ye Y. et al. (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27: 461–466.
32. Cohen D. Koopmans M. Kremer Hovinga I. Berger S. Roos van Groningen M. Steup-Beekman G. et al. (2008) Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 58: 2460–2469.
33. Cornacchia E. Golbus J. Maybaum J. Strahler J. Hanash S. Richardson B. (1988) Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140: 2197–2200.
34. Crispin J. Keenan B. Finnell M. Bermas B. Schur P. Massarotti E. et al. (2010 a) Expression of CD 44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum 62: 1431–1437.
35. Crispin J. Liossis S. Kis-Toth K. Lieberman L. Kyttaris V. Juang Y. et al. (2010 b) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16 (2): 47–57.
36. Crispin J. Oukka M. Bayliss G. Cohen R. van Beek C. Stillman I. et al. (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181: 8761–8766.
37. Crispin J. Tsokos G. (2010 a) IL-17 in systemic lupus erythematosus. J Biomed Biotechnol 2010: 943254.
38. Crispin J. Tsokos G. (2010 b) Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 22: 499–503.
39. Crow M. (2007) Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 316: 359–386.
40. Dai R. Ahmed S. (2011) MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 157: 163–179.
41. Dai Y. Huang Y. Tang M. Lv T. Hu C. Tan Y. et al. (2007) Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 16: 939–946.
42. Dai Y. Sui W. Lan H. Yan Q. Huang H. Huang Y. (2009 a) Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 29: 749–754.
43. Dai Z. Turtle C. Booth G. Riddell S. Gooley T. Stevens A. et al. (2009 b) Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 206: 793–805.
44. Davis L. Hutcheson J. Mohan C. (2011) The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res 31: 781–789.
45. Deapen D. Escalante A. Weinrib L. Horwitz D. Bachman B. Roy-Burman P. et al. (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35: 311–318.
46. Deng G. Tsokos G. (2008) Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 181: 4019–4026.
47. Deng Y. Tsao B. (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6: 683–692.
48. Dong L. Hu S. Chen F. Lei X. Tu W. Yu Y. et al. (2010) Increased expression of ganglioside GM 1 in peripheral CD4+ T cells correlates soluble form of CD 30 in systemic lupus erythematosus patients. J Biomed Biotechnol 2010: 569053.
49. Doreau A. Belot A. Bastid J. Riche B. Trescol-Biemont M. Ranchin B. et al. (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10: 778–785.
50. Elkon K. Wiedeman A. (2012) Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 24: 499–505.
51. Ettinger R. Kuchen S. Lipsky P. (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223: 60–86.
52. Fabian M. Sonenberg N. Filipowicz W. (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351–379.
53. Feng X. Wu H. Grossman J. Hanvivadhanakul P. FitzGerald J. Park G. et al. (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54: 2951–2962.
54. Fields P. Kim S. Flavell R. (2002) Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J Immunol 169: 647–650.
55. Flesher D. Sun X. Behrens T. Graham R. Criswell L. (2010) Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 6: 461–479.
56. Fraga M. Ballestar E. Paz M. Ropero S. Setien F. Ballestar M. et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102: 10604–10609.
57. Gabay C. McInnes I. (2009) The biological and clinical importance of the ‘new generation’ cytokines in rheumatic diseases. Arthritis Res Ther 11: 230.
58. Gao H. Campbell S. Burkly L. Jakubowski A. Jarchum I. Banas B. et al. (2009) TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 46: 24–35.
59. Gomez-Puerta J. Burlingame R. Cervera R. (2008) Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev 7: 606–611.
60. Grootscholten C. Dieker J. McGrath F. Roos A. Derksen R. van der Vlag J. et al. (2007) A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis 66: 693–696.
61. Gutierrez-Adrianzen O. Koutouzov S. Mota R. das Chagas Medeiros M. Bach J. de Holanda Campos H. (2006) Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 33: 1538–1544.
62. Harder T. (2004) Lipid raft domains and protein networks in T-cell receptor signal transduction. Curr Opin Immunol 16: 353–359.
63. Harigai M. Kawamoto M. Hara M. Kubota T. Kamatani N. Miyasaka N. (2008) Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 181: 2211–2219.
64. Herbst R. Liu Z. Jallal B. Yao Y. (2012) Biomarkers for systemic lupus erythematosus. Int J Rheum Dis 15: 433–444.
65. Hinze C. Suzuki M. Klein-Gitelman M. Passo M. Olson J. Singer N. et al. (2009) Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 60: 2772–2781.
66. Hoffman R. (2004) T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 113: 4–13.
67. Hooks J. Moutsopoulos H. Geis S. Stahl N. Decker J. Notkins A. (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301: 5–8.
68. Horak P. Hermanova Z. Zadrazil J. Ciferska H. Ordeltova M. Kusa L. et al. (2006) C1q complement component and -antibodies reflect SLE activity and kidney involvement. Clin Rheumatol 25: 532–536.
69. Horvath L. Czirjak L. Fekete B. Jakab L. Pozsonyi T. Kalabay L. et al. (2001) High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 19: 667–672.
70. Hu N. Qiu X. Luo Y. Yuan J. Li Y. Lei W. et al. (2008) Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 35: 804–810.
71. Hughes T. Sawalha A. (2011) The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 13: 245.
72. Hughes T. Webb R. Fei Y. Wren J. Sawalha A. (2010) DNA methylome in human CD4+ T cells identifies transcriptionally repressive and non-repressive methylation peaks. Genes Immun 11: 554–560.
73. Hung W. Chen Y. Lan J. Chen H. Chen Y. Chen D. et al. (2011) Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus 20: 1404–1410.
74. Illei G. Tackey E. Lapteva L. Lipsky P. (2004 a) Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 50: 1709–1720.
75. Illei G. Tackey E. Lapteva L. Lipsky P. (2004 b) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50: 2048–2065.
76. Javierre B. Fernandez A. Richter J. Al-Shahrour F. Martin-Subero J. Rodriguez-Ubreva J. et al. (2010) Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 20: 170–179.
77. Jeffries M. Dozmorov M. Tang Y. Merrill J. Wren J. Sawalha A. (2011) Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 6: 593–601.
78. Jeffries M. Sawalha A. (2011) Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumatol 6: 423–439.
79. Juang Y. Peoples C. Kafri R. Kyttaris V. Sunahori K. Kis-Toth K. et al. (2011) A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report. Lupus 20: 243–249.
80. Jury E. Flores-Borja F. Kabouridis P. (2007) Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol 18: 608–615.
81. Jury E. Isenberg D. Mauri C. Ehrenstein M. (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177: 7416–7422.
82. Jury E. Kabouridis P. Flores-Borja F. Mageed R. Isenberg D. (2004) Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 113: 1176–1187.
83. Kabouridis P. Jury E. (2008) Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett 582: 3711–3718.
84. Kalunian K. Chatham W. Massarotti E. Reyes-Thomas J. Harris C. Furie R. et al. (2012) Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum 64: 4040–4047.
85. Kaplan M. Lu Q. Wu A. Attwood J. Richardson B. (2004) Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol 172: 3652–3661.
86. Karageorgas T. Tseronis D. Mavragani C. (2011) Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed Biotechnol 2011: 273907.
87. Kiani A. Johnson K. Chen C. Diehl E. Hu H. Vasudevan G. et al. (2009) Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 36: 2224–2230.
88. Kiani A. Wu T. Fang H. Zhou X. Ahn C. Magder L. et al. (2012) Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis. J Rheumatol 39: 1231–1237.
89. Kirou K. Lee C. George S. Louca K. Peterson M. Crow M. (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52: 1491–1503.
90. Korn T. Bettelli E. Oukka M. Kuchroo V. (2009) IL-17 and Th 17 Cells. Annu Rev Immunol 27: 485–517.
91. Koutouzov S. Jeronimo A. Campos H. Amoura Z. (2004) Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 30: 529–558.
92. Krishnan S. Nambiar M. Warke V. Fisher C. Mitchell J. Delaney N. et al. (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 172: 7821–7831.
93. Landolt-Marticorena C. Bonventi G. Lubovich A. Ferguson C. Unnithan T. Su J. et al. (2009) Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 68: 1440–1446.
94. Laurent L. Wong E. Li G. Huynh T. Tsirigos A. Ong C. et al. (2010) Dynamic changes in the human methylome during differentiation. Genome Res 20: 320–331.
95. Li T. Zhang T. Chen G. Zhu Q. Tao J. Pan H. et al. (2010) Low level of serum interleukin 27 in patients with systemic lupus erythematosus. J Investig Med 58: 737–739.
96. Lin S. Hsieh S. Lin Y. Lee C. Tsai M. Lai L. et al. (2012) A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL 10 and IL1R2 promoters is associated with disease activity. Genes Immun 13: 214–220.
97. Liu C. Manzi S. Kao A. Navratil J. Ahearn J. (2010) Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside. Rheum Dis Clin North Am 36: 161–172.
98. Liu Y. Kuick R. Hanash S. Richardson B. (2009) DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol 130: 213–224.
99. Lu Q. Kaplan M. Ray D. Zacharek S. Gutsch D. Richardson B. (2002) Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 46: 1282–1291.
100. Lu Q. Wu A. Richardson B. (2005) Demethylation of the same promoter sequence increases CD 70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 174: 6212–6219.
101. Lu Q. Wu A. Tesmer L. Ray D. Yousif N. Richardson B. (2007) Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 179: 6352–6358.
102. Luger K. Dechassa M. Tremethick D. (2012) New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? Nat Rev Mol Cell Biol 13: 436–447.
103. Mackay F. Schneider P. (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491–502.
104. Manderson A. Botto M. Walport M. (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22: 431–456.
105. Manolio T. Collins F. Cox N. Goldstein D. Hindorff L. Hunter D. et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747–753.
106. Manson J. Ma A. Rogers P. Mason L. Berden J. van der Vlag J. et al. (2009) Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther 11 (5): R154.
107. Marto N. Bertolaccini M. Calabuig E. Hughes G. Khamashta M. (2005) Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64: 444–448.
108. Matrat A. Veysseyre-Balter C. Trolliet P. Villar E. Dijoud F. Bienvenu J. et al. (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20: 28–34.
109. McKinney E. Lyons P. Carr E. Hollis J. Jayne D. Willcocks L. et al. (2010) A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16: 586–591, 581p following 591.
110. Merrill J. Wallace D. Petri M. Kirou K. Yao Y. White W. et al. (2011) Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 70: 1905–1913.
111. Meyer O. Nicaise-Roland P. Cadoudal N. Grootenboer-Mignot S. Palazzo E. Hayem G. et al. (2009) Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther 11 (3): R87.
112. Min D. Kim S. Park S. Seo Y. Kang H. Kim W. et al. (2002) Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 20: 13–18.
113. Mishra J. Ma Q. Prada A. Mitsnefes M. Zahedi K. Yang J. et al. (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14: 2534–2543.
114. Mitoma H. Horiuchi T. Kimoto Y. Tsukamoto H. Uchino A. Tamimoto Y. et al. (2005) Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 16: 609–615.
115. Mohan C. Adams S. Stanik V. Datta S. (1993) Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177: 1367–1381.
116. Mok C. (2010) Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010: 638413.
117. Mok C. Lau C. (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56 (7): 481–490.
118. Moore P. Belvedere O. Orr A. Pieri K. LaFleur D. Feng P. et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260–263.
119. Moroni G. Radice A. Giammarresi G. Quaglini S. Gallelli B. Leoni A. et al. (2009) Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 68: 234–237.
120. Moroni G. Trendelenburg M. Papa N. Quaglini S. Raschi E. Panzeri P. et al. (2001) Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37: 490–498.
121. Moser K. Kelly J. Lessard C. Harley J. (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10: 373–379.
122. Mosley K. Tam F. Edwards R. Crozier J. Pusey C. Lightstone L. (2006) Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 45: 1497–1504.
123. Moulton V. Tsokos G. (2011) Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 13: 207.
124. Nardelli B. Belvedere O. Roschke V. Moore P. Olsen H. Migone T. et al. (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198–204.
125. Nath S. Kilpatrick J. Harley J. (2004) Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 16: 794–800.
126. Nikpour M. Dempsey A. Urowitz M. Gladman D. Barnes D. (2008) Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis 67: 1069–1075.
127. Noris M. Bernasconi S. Casiraghi F. Sozzani S. Gotti E. Remuzzi G. et al. (1995) Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73: 804–809.
128. O'Brien R. Roark C. Born W. (2009) IL-17-producing gammadelta T cells. Eur J Immunol 39: 662–666.
129. Obermoser G. Pascual V. (2010) The interferon-alpha signature of systemic lupus erythematosus. Lupus 19: 1012–1019.
130. Oelke K. Lu Q. Richardson D. Wu A. Deng C. Hanash S. et al. (2004) Overexpression of CD 70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 50: 1850–1860.
131. Ouyang W. Kolls J. Zheng Y. (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454–467.
132. Pan W. Zhu S. Yuan M. Cui H. Wang L. Luo X. et al. (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184: 6773–6781.
133. Pers J. Daridon C. Devauchelle V. Jousse S. Saraux A. Jamin C. et al. (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050: 34–39.
134. Petri M. Singh S. Tesfasyone H. Dedrick R. Fry K. Lal P. et al. (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18: 980–989.
135. Petri M. Stohl W. Chatham W. McCune W. Chevrier M. Ryel J. et al. (2008) Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58: 2453–2459.
136. Pickering M. Botto M. (2010) Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 6: 490–493.
137. Pickering M. Botto M. Taylor P. Lachmann P. Walport M. (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76: 227–324.
138. Pitashny M. Schwartz N. Qing X. Hojaili B. Aranow C. Mackay M. et al. (2007) Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 56: 1894–1903.
139. Potlukova E. Kralikova P. (2008) Complement component c1q and anti-c1q antibodies in theory and in clinical practice. Scand J Immunol 67: 423–430.
140. Rahman A. Isenberg D. (2008) Systemic lupus erythematosus. N Engl J Med 358: 929–939.
141. Rauch T. Wu X. Zhong X. Riggs A. Pfeifer G. (2009) A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A 106: 671–678.
142. Renaudineau Y. Youinou P. (2011) Epigenetics and autoimmunity, with special emphasis on methylation. Keio J Med 60: 10–16.
143. Richardson B. Scheinbart L. Strahler J. Gross L. Hanash S. Johnson M. (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33: 1665–1673.
144. Ritterhouse L. Crowe S. Niewold T. Merrill J. Roberts V. Dedeke A. et al. (2011) B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum 63: 3931–3941.
145. Roh T. Cuddapah S. Zhao K. (2005) Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 19: 542–552.
146. Rose T. Grutzkau A. Hirseland H. Huscher D. Dahnrich C. Dzionek A. et al. (2012) IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis, in press.
147. Rovin B. Doe N. Tan L. (1996) Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 27: 640–646.
148. Rovin B. Song H. Birmingham D. Hebert L. Yu C. Nagaraja H. (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16: 467–473.
149. Rovin B. Zhang X. (2009) Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol 4: 1858–1865.
150. Rubinstein T. Pitashny M. Levine B. Schwartz N. Schwartzman J. Weinstein E. et al. (2010) Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 49: 960–971.
151. Santer D. Yoshio T. Minota S. Moller T. Elkon K. (2009) Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 182: 1192–1201.
152. Sanz A. Justo P. Sanchez-Nino M. Blanco-Colio L. Winkles J. Kreztler M. et al. (2008) The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 19: 695–703.
153. Sarzi-Puttini P. Atzeni F. Iaccarino L. Doria A. (2005) Environment and systemic lupus erythematosus: an overview. Autoimmunity 38: 465–472.
154. Schwartz N. Michaelson J. Putterman C. (2007) Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 1109: 265–274.
155. Schwartz N. Rubinstein T. Burkly L. Collins C. Blanco I. Su L. et al. (2009) Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 11 (5): R143.
156. Schwartz N. Su L. Burkly L. Mackay M. Aranow C. Kollaros M. et al. (2006) Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 27: 242–250.
157. Shah K. Lee W. Lee S. Kim S. Kang S. Craft J. et al. (2010) Dysregulated balance of Th 17 and Th 1 cells in systemic lupus erythematosus. Arthritis Res Ther 12 (2): R53.
158. Shen N. Liang D. Tang Y. de Vries N. Tak P. (2012) MicroRNAs-novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol 8: 701–709.
159. Sinico R. Rimoldi L. Radice A. Bianchi L. Gallelli B. Moroni G. (2009) Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci 1173: 47–51.
160. Snowden A. Gregory P. Case C. Pabo C. (2002) Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 12: 2159–2166.
161. Stagakis E. Bertsias G. Verginis P. Nakou M. Hatziapostolou M. Kritikos H. et al. (2011) Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD 4 expression. Ann Rheum Dis 70: 1496–1506.
162. Stohl W. Metyas S. Tan S. Cheema G. Oamar B. Xu D. et al. (2003) B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48: 3475–3486.
163. Suzuki M. Ross G. Wiers K. Nelson S. Bennett M. Passo M. et al. (2007) Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol 22: 2047–2057.
164. Suzuki M. Wiers K. Brooks E. Greis K. Haines K. Klein-Gitelman M. et al. (2009) Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res 65: 530–536.
165. Suzuki M. Wiers K. Klein-Gitelman M. Haines K. Olson J. Onel K. et al. (2008) Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 23: 403–412.
166. Tang Y. Luo X. Cui H. Ni X. Yuan M. Guo Y. et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60: 1065–1075.
167. Te J. Dozmorov I. Guthridge J. Nguyen K. Cavett J. Kelly J. et al. (2010) Identification of unique microRNA signature associated with lupus nephritis. PloS ONE 5 (5): e10344.
168. Tian S. Li J. Wang L. Liu T. Liu H. Cheng G. et al. (2007) Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 56: 304–310.
169. Trachtman H. Christen E. Cnaan A. Patrick J. Mai V. Mishra J. et al. (2006) Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 21: 989–994.
170. Trendelenburg M. Lopez-Trascasa M. Potlukova E. Moll S. Regenass S. Fremeaux-Bacchi V. et al. (2006) High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dialysis Transplant 21: 3115–3121.
171. Trendelenburg M. Marfurt J. Gerber I. Tyndall A. Schifferli J. (1999) Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 42: 187–188.
172. Tsokos G. (2011) Systemic lupus erythematosus. N Engl J Med 365: 2110–2121.
173. Tucci M. Barnes E. Sobel E. Croker B. Segal M. Reeves W. et al. (2004) Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 50: 1842–1849.
174. Vila L. Molina M. Mayor A. Cruz J. Rios-Olivares E. Rios Z. (2007) Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 26: 718–722.
175. Wada T. Yokoyama H. Su S. Mukaida N. Iwano M. Dohi K. et al. (1996) Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 49: 761–767.
176. Wang G. Tam L. Li E. Kwan B. Chow K. Luk C. et al. (2011) Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. J Rheumatol 37: 2516–2522.
177. Wang H. Peng W. Ouyang X. Li W. Dai Y. (2012) Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res 160: 198–206.
178. Watson L. Beresford M. (2012) Urine biomarkers in juvenile-onset SLE nephritis. Pediatr Nephrol, in press.
179. Watson L. Midgley A. Pilkington C. Tullus K. Marks S. Holt R. et al. (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21: 496–501.
180. Weckerle C. Niewold T. (2011) The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 40: 42–49.
181. Williamson W. Pinto I. (2012) Histones and genome integrity. Front Biosci 17: 984–995.
182. Wilson C. Rowell E. Sekimata M. (2009) Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9: 91–105.
183. Winfield J. Shaw M. Silverman L. Eisenberg R. Wilson H. III Koffler D. (1983) Intrathecal IgG synthesis and blood–brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 74: 837–844.
184. Winkles J. (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411–425.
185. Wong C. Ho C. Li E. Lam C. (2000) Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th 2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9: 589–593.
186. Xiao C. Rajewsky K. (2009) MicroRNA control in the immune system: basic principles. Cell 136: 26–36.
187. Yang C. Hsieh S. Li K. Wu C. Lu M. Tsai C. et al. (2012) Urinary neutrophil gelatinase-associated lipocalin is a potential biomarker for renal damage in patients with systemic lupus erythematosus. J Biomed Biotechnol 2012: 759313.
188. Yang J. Chu Y. Yang X. Gao D. Zhu L. Wan L. et al. (2009) Th 17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60: 1472–1483.
189. Yao Y. Higgs B.W. Richman L. White B. Jallal B. (2010) Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 12(Suppl. 1): S6.
190. Ytterberg S. Schnitzer T. (1982) Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25: 401–406.
191. Yu B. Shao Y. Yue X. Zhang J. Guan M. Wan J. et al. (2011) Copy number variations of Interleukin-12B and T-bet are associated with systemic lupus erythematosus. Rheumatology (Oxford) 50: 1201–1205.
192. Zhang J. Roschke V. Baker K. Wang Z. Alarcon G. Fessler B. et al. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166: 6–10.
193. Zhang X. Nagaraja H. Nadasdy T. Song H. McKinley A. Prosek J. et al. (2012) A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int 81: 401–406.
194. Zhang Z. Kyttaris V. Tsokos G. (2009) The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 183: 3160–3169.
195. Zhang Z. Song L. Maurer K. Petri M. Sullivan K. (2010) Global H 4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun 11: 124–133.
196. Zhao M. Tang J. Gao F. Wu X. Liang Y. Yin H. et al. (2010 a) Hypomethylation of IL 10 and IL 13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol 2010: 931018.
197. Zhao S. Wang Y. Liang Y. Zhao M. Long H. Ding S. et al. (2011) MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 63: 1376–1386.
198. Zhao X. Tang Y. Qu B. Cui H. Wang S. Wang L. et al. (2010 b) MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF 13 in systemic lupus erythematosus. Arthritis Rheum 62: 3425–3435.